Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05350072 · ClinicalTrials.gov registry record · Phase 3
Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
A Phase 3 study of Sjogren Syndrome, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 276
- Enrollment target
- 20
- Study locations
NCT05350072 is a Phase 3 study of Sjogren Syndrome that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 276 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT05350072, a Phase 3 study of Sjogren Syndrome, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 276 participants
- Enrollment target
- 20
- Study locations
Study Summary
A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-1)
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL VAY736
Study Locations (20)
Texas
- Precision Comprehensive Research - Colleyville
- Metroplex Clinical Research - Dallas
- Baylor College Of Medicine - Houston
- Houston Rheumatology & Arthrit - Katy
Other
- Novartis Investigative Site - Graz
- Novartis Investigative Site - Stockerau
- Novartis Investigative Site - Leuven
California
- Medvin Clinical Research - Van Nuys
Florida
- West Broward Rheumatology Associates Inc - Tamarac
Indiana
- Indiana Univ School of Dentistry - Indianapolis
Louisiana
- Ochsner Health System - Baton Rouge
Maryland
- The John Hopkins Jerome L Greene Sjogren - Baltimore
New York
- Winthrop University Hospital - Mineola
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2022-07-28 |
| Est. Completion | 2027-05-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05350072
The ClinicalTrials.gov registry entry for NCT05350072 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sjogren Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05350072 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Texas, Other, California.
Frequently Asked Questions
What is clinical trial NCT05350072 about?
NCT05350072 is a clinical study titled "Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome". A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-1)
What is the current status of trial NCT05350072?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 276 participants. The study started on 2022-07-28. Estimated completion is 2027-05-06.
What conditions does trial NCT05350072 study?
This clinical trial studies the following conditions: Sjogren Syndrome.
What interventions are being tested in trial NCT05350072?
The interventions under investigation include: Placebo (OTHER), VAY736 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05350072?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05350072 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sjogren Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.